MEDICINES CO /DE Form SC 13G/A November 12, 2004

OMB APPROVAL

OMB Number: 3235-0145

Expires: December 31, 2005

Estimated average burden hours per response. . . 11

United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

	The Medicines Company
	(Name of Issuer)
	Common Stock
	(Title of Class of Securities)
	584688105
	(CUSIP Number)
	December 31, 2003
	(Date of Event Which Requires Filing This Statement)
Check the appropriate box to	designate the rule pursuant to which this Schedule is filed:

[] [**X**]

[]

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Page 1 of 7

^{*}The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. <u>584688</u>	8105	
Name(s) of Reporting Per	ersons:	BB Biotech AG
I.R.S. Identification Nos	. of above persons (entities only):	N/A
2. Check the Appropriate B	Box if a Member of a Group (See Instructions):	
(a) [X]		
(b) []		
3. SEC Use Only:		
4. Citizenship or Place of C	Organization:	Switzerland
Number of Shares Beneficially Owned by Each Reporting Person with	ole Voting Power:	0
	hared Voting Power:	4,136,419
	ole Dispositiveower:	0
	hared Dispositiveower:	4,727,854 ⁽¹⁾
Aggregate Amount Ber by Each Reporting Pers	neficially Owned	4,727,854 ⁽¹⁾
10. Check if the Aggregate	Amount in Row (9) Excludes Certain Shares (See Instructions):	[]
11. Percent of Class Repres	sented by Amount in Row (9):	9.9%
12. Type of Reporting Pers	on (See Instructions):	нс,со
(1) Includes 591,435 shares of Com	mon Stock issuable to Biotech Growth N.V. upon the exercise of warr	ants.

Page 2 of 7

CUSIP No. 58	84688105	
1. Name(s) of Reporti	ing Persons:	Biotech Growth N.V.
I.R.S. Identification	n Nos. of above persons (entities only):	N/A
2. Check the Appropr	iate Box if a Member of a Group (See Instructions):	
(a) [X]		
(b) []		
3. SEC Use Only:		
4. Citizenship or Place	e of Organization:	Netherlands Antilles
Number of Shares Beneficially Owned by Each Reporting Person with	Sole Voting Power:	0
with 6	5. Shared Voting Power:	4,136,419
7	7. Sole Dispositive Power:	0
8	S. Shared Dispositive Power:	4,727,854 ⁽¹⁾
9. Aggregate Amour by Each Reporting	nt Beneficially Owned g Person:	4,727,854(1)
10. Check if the Aggr	egate Amount in Row (9) Excludes Certain Shares (See Instructions):	[]
11. Percent of Class F	Represented by Amount in Row (9):	9.9%
	g Person (See Instructions):	СО
(1) Includes 591,435 shares of	Common Stock issuable to Biotech Growth N.V. upon the exercise of w	varrants.

Page 3 of 7

CUSIP No58	4688105	
Name(s) of Reporting	ng Persons:	Biotech Target N.V.
I.R.S. Identification	Nos. of above persons (entities only):	N/A
2. Check the Appropri	ate Box if a Member of a Group (See Instructions):	
(a) [X]		
(b) []		
3. SEC Use Only: _		
4. Citizenship or Place	of Organization:	Netherlands Antilles
Number of Shares Beneficially Owned by Each Reporting Person	Sole Voting Power:	0
with 6.	Shared Voting Power:	4,136,419
7.	Sole Dispositive Power:	0
8.	Shared Dispositive Power:	4,727,854 ⁽¹⁾
Aggregate Amoun by Each Reporting	t Beneficially Owned Person:	4,727,854 ⁽¹⁾
10. Check if the Aggre	egate Amount in Row (9) Excludes Certain Shares (See Instructions):	[]
11. Percent of Class R	epresented by Amount in Row (9):	9.9%
12. Type of Reporting	Person (See Instructions):	СО
(1) Includes 591,435 shares of	Common Stock issuable to Biotech Growth N.V. upon the exercise of w	varrants.

Page 4 of 7

Note: This amendment is being filed to correct the filing party information by adding Biotech Target N.V. as a joint filer. This information was inadvertently not included in the Schedule 13G/A filed on February 17, 2004. The beneficial ownership of the group has also been updated to reflect its ownership as of November 11, 2004.

Item 2					
2(a)	Names of Persons Filing: <u>BB Biotech AG (BB Biotech), on behalf of its wholly-owned subsidiaries Biotech Target N.V. (Biotech Target) and Biotech Growth N.V. (Biotech Growth).</u>				
2(b)	Address of Principal Business Office or, if none, Residence:				
	BB B	Biotech AG: Vorderga	sse 3, CH-8200 Schaffh	nausen, Switzerland	
	Biote	ech Target N.V. and Biot	ech Growth N.V.: De R	Ruyterkade 62, Willemstad, Curacao	o, Netherlands Antilles
2(c)	Citize	enship: Sw	tzerland		
2(d)	Title	of Class of Securities	Common Sto	ock, \$0.0001 par value	
2(e) Item 4. O			584688105		
Provid	e the fol	lowing information regard	ing the aggregate number	er and percentage of the class of securi	ities of the issuer identified in Item 1.
(a)	Amou	nt beneficially owned:		4,727,854(1)	
(b)	Percer	nt of class:		9.9%	
(c)	Numb	er of shares as to which th	e person has:		
	(i)	Sole power to vote or to	o direct the vote		0
	(ii)	Shared power to vote o	r to direct the vote		4,136,419
	(iii)	Sole power to dispose of	or to direct the disposition	on of	0
	(iv)	Shared power to dispos	e or to direct the disposi	tion of	4,727,854(1)
		ntion and Classification on trol Person.	f the Subsidiary Which	Acquired the Security Being Repor	rted on By the Parent Holding
		nt is filed jointly by BB B bsidiaries of BB Biotech.		and Biotech Target. Biotech Grow	th and Biotech Target are
(1) Include	es 591,4	35 shares of Common Sto	ck issuable to Biotech G	rowth N.V. upon the exercise of warra	ants.
			P	age 5 of 7	

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB BIOTECH AG

/s/ ROLAND MAIER	/s/ ADRIAN BRUENGGER
------------------	----------------------

By:Roland MaierBy:Adrian BruenggerIts:Authorized SignatoryIts:Authorized SignatoryDate:November 11, 2004Date:November 11, 2004

BIOTECH GROWTH N.V.

/s/ ROLAND MAIER /s/ ADRIAN BRUENGGER

By:Roland MaierBy:Adrian BruenggerIts:Authorized SignatoryIts:Authorized SignatoryDate:November 11, 2004Date:November 11, 2004

BIOTECH TARGET N.V.

/s/ ROLAND MAIER /s/ ADRIAN BRUENGGER

By:Roland MaierBy:Adrian BruenggerIts:Authorized SignatoryIts:Authorized SignatoryDate:November 11, 2004Date:November 11, 2004

Page 6 of 7

EXHIBIT A

Exhibit A

Joint Filing Statement

Pursuant to Rule 13d-1(f)(1), we, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

BB Biotech AG Date: November 11, 2004 By: /s/ Roland Maier Signatory Authority Name: **Roland Maier** Title: **Signatory Authority** Biotech Growth N.V. /s/ Roland Maier Date: November 11, 2004 By: Signatory Authority Name: **Roland Maier Signatory Authority** Title: Biotech Target N.V. Date: November 11, 2004 By: /s/ Roland Maier Signatory Authority **Roland Maier** Name:

Title:	Signatory Authority

Page 7 of 7